Riskpilot← Back to searchSign inGet full accessExtem Pharma AB
ABActiveOrg 5594742198Vallongatan 1 SkeppetManufacture of pharmaceutical preparations · NACE 2120Est. 20241-4 employees
Revenue 2024
SEK -2
EBITDA margin
4497450.0%
Equity ratio
45.3%
Financial strength
Net profit 2024
SEK -89K
| Revenue | SEK -2 | — |
| EBITDA | SEK -90K | — |
| Net profit | SEK -89K | — |
| Total assets | SEK 410K | — |
| Equity | SEK 186K | — |
| Employees | — | — |
Legal name
Extem Pharma AB
Org number
5594742198
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
1 mars 2024
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska direkt eller genom dotterbolag bedriva utveckling och tillverkning av läkemedel samt medicinsk, odontologisk, veterinärmedicinsk och farmaceutisk konsult- verksamhet. Bolaget skall även bedriva handel med värdepapper och andra finansiella instrument.
Address
Vallongatan 1 Skeppet
Email
information@extempharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | −0 |
| Staff expenses | −66 |
| EBITDA | −90 |
| Depreciation & amort. | — |
| EBIT | −90 |
| Net financials | 1 |
| Profit before tax | −89 |
| Tax | — |
| Net profit | −89 |
| Item | 2024 |
|---|---|
| Total assets | 410 |
| Equity | 186 |
| Long-term debt | — |
| Short-term debt | 224 |
| Total debt | 224 |
EBITDA margin
-8994900.0%
This company
15.8%
Market median
-56929847% vs market
20242024
Equity ratio
45.3%
This company
38.2%
Market median
+19% vs market
20242024
Return on equity
-48.0%
This company
18.4%
Market median
-361% vs market
20242024
Net profit margin
-8926600.0%
This company
8.1%
Market median
-110205038% vs market
20242024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20242024
Debt / equity
1.21×
This company
0.62×
Market median
-95% vs market
20242024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SI Chief Executive Officer | Chief Executive Officer | 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2024 | |
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Former (2) | ||
| Board of Directors | 2024 – 2025 | |
| Chairman | 2024 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Extem Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Susanne Inga-Lill Bredenberg | Chief Executive Officer | 0 companies |
| Carl Jonas Lindh | Board of Directors | 0 companies |
| Ingemar Mattias Paulsson | Board of Directors | 0 companies |
| Paul Olof Henrik Rönnberg | Chairman | 0 companies |
| Christel Anna Sofie Bergström | Chairman | 0 companies |
| Bo Sverre Bengtsson | Board of Directors | 0 companies |